Recent studies have converged on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopaminergic neurotransmission. While GIP agonists are increasingly employed for managing type 2 T2DM, their unexpected consequences on reward circuits, specifically governed by DA networks, are gaining substa